Osiris Announces Electronically Available Case Study in a Peer-Reviewed Journal: Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
June 14, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., June 14, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Appoints David White to its Board of Directors
May 31, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., May 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30th, 2017, appointed Mr....
Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
April 13, 2017 17:15 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
April 04, 2017 17:15 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., April 04, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Therapeutics Announces Change in its Board of Directors
March 31, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), announced today the passing of one of its Board Members, Yves Huwyler. "It deeply saddens me to...
Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
March 30, 2017 18:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
March 27, 2017 17:15 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 27, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Receives Notice of Delisting from NASDAQ
March 10, 2017 17:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) announced today that the Company received a letter from the NASDAQ Stock Market (“NASDAQ”)...
Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
February 10, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7th, 2017, confirmed the...
Osiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal
January 19, 2017 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that the study “A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two...